Found: 18
Select item for more details and to access through your institution.
SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).
- Published in:
- Clinical & Translational Oncology, 2022, v. 24, n. 4, p. 703, doi. 10.1007/s12094-022-02803-0
- By:
- Publication type:
- Article
Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial.
- Published in:
- Cancers, 2022, v. 14, n. 10, p. 2393, doi. 10.3390/cancers14102393
- By:
- Publication type:
- Article
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
- Published in:
- Neuro-Oncology, 2021, v. 23, n. 8, p. 1415, doi. 10.1093/neuonc/noaa115
- By:
- Publication type:
- Article
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1851, doi. 10.1093/neuonc/noaa107
- By:
- Publication type:
- Article
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 5, p. 684, doi. 10.1093/neuonc/noz222
- By:
- Publication type:
- Article
Defining EGFR amplification status for clinical trial inclusion.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 10, p. 1263, doi. 10.1093/neuonc/noz096
- By:
- Publication type:
- Article
Phase II trial of dacomitinib, a pan‒human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
- Published in:
- Neuro-Oncology, 2017, v. 19, n. 11, p. 1522, doi. 10.1093/neuonc/nox105
- By:
- Publication type:
- Article
SEOM-GEINO clinical guidelines for grade 2 gliomas (2023).
- Published in:
- Clinical & Translational Oncology, 2024, v. 26, n. 11, p. 2856, doi. 10.1007/s12094-024-03456-x
- By:
- Publication type:
- Article
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).
- Published in:
- Targeted Oncology, 2020, v. 15, n. 5, p. 613, doi. 10.1007/s11523-020-00754-6
- By:
- Publication type:
- Article
A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer
- Published in:
- Oncologist, 2019, v. 24, n. 11, p. e1024, doi. 10.1634/theoncologist.2017-0664
- By:
- Publication type:
- Article
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab.
- Published in:
- Oncologist, 2011, v. 16, n. 2, p. 136, doi. 10.1634/theoncologist.2010-0154
- By:
- Publication type:
- Article
Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study.
- Published in:
- Oncology Letters, 2017, v. 13, n. 6, p. 4093, doi. 10.3892/ol.2017.5988
- By:
- Publication type:
- Article
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial.
- Published in:
- Neuro-Oncology, 2024, v. 26, n. 9, p. 1670, doi. 10.1093/neuonc/noae053
- By:
- Publication type:
- Article
3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.
- Published in:
- Neuro-Oncology, 2024, v. 26, n. 7, p. 1302, doi. 10.1093/neuonc/noae037
- By:
- Publication type:
- Article
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
- Published in:
- Neuro-Oncology, 2023, v. 25, n. 6, p. 1113, doi. 10.1093/neuonc/noac263
- By:
- Publication type:
- Article
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
- Published in:
- Neuro-Oncology, 2023, v. 25, n. 1, p. 123, doi. 10.1093/neuonc/noac099
- By:
- Publication type:
- Article
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 755, doi. 10.1093/neuonc/noab243
- By:
- Publication type:
- Article
Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival.
- Published in:
- Neurocirugía, 2019, v. 30, n. 1, p. 11, doi. 10.1016/j.neucir.2018.06.004
- By:
- Publication type:
- Article